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AbstrAct
Objectives To evaluate the sensitivity to change of 
ultrasound structural gout lesions, as defined by the 
Outcome Measures in rheumatology (OMeracT) 
ultrasound group, in patients with gout during urate- 
lowering therapy (UlT).
Methods Ultrasound (28 joints, 26 tendons) was 
performed in patients with microscopically verified 
gout initiating or increasing UlT and repeated after 3 
and 6 months. Joints and tendons were evaluated by 
ultrasound for presence of the OMeracT structural gout 
lesions—double contour sign (Dc), tophus, aggregates 
and erosion—scored binarily. a sum score was calculated 
at patient and lesion level. changes at 3 and 6 months in 
patient sum scores and lesion scores at different locations 
were evaluated.
Results 50 patients (48 men), mean age 68.9 (range, 
30–88) years, were included. Ultrasound showed a 
statistically significant decrease in Dc and tophus sum 
scores from 0 months (3.16 and 2.68, respectively) to 3 
months (2.33 and 2.43) and 6 months (1.34 and 1.83) 
(all p<0.002). The aggregate sum score only decreased 
significantly from 3 to 6 months (6.02 to 5.02, p=0.002), 
whereas erosion sum score remained almost unchanged. 
all four structural lesions were most commonly found in 
metatarsophalangeal (MTP) 1 joints (>1 lesions bilaterally), 
and furthermore MTP2–4 and knee joints were common 
sites especially for Dc. likewise, these regions were the 
locations with most pronounced changes in scores.
Conclusion Ultrasound assessment of the OMeracT 
structural gout lesions scored binarily seems to be a 
useful tool for monitoring urate depositions during UlT. 
Particularly Dc and tophus showed sensitivity to change 
after only 3 months of treatment.
InTROduCTIOn
Gout is the most common inflammatory joint 
disease in Western developed countries.1 If 
treated properly, gout flares can be prevented, 
joint damage related to tophi formation can 
be minimised, further crystal formation can 
be prevented and existing crystal deposits can 
be dissolved.1 If poorly controlled, gout may 
lead to renal failure, cardiovascular disease, 
increased morbidity and mortality and poorer 
quality of life.2 3 Therefore, appropriate 
management of gout is essential.
Monitoring of patients with gout has tradi-
tionally been based on clinical assessment 
combined with p- urate levels. Studies indicate 
that ultrasound is a useful tool when diag-
nosing gout,4–7 but little is known about its 
ability to monitor treatment effect.
Monosodium urate crystals reflect ultra-
sound beams more strongly than surrounding 
tissues such as unmineralised hyaline carti-
lage or synovial tissue. Crystalline material 
can therefore be detected by ultrasound as 
a bright, hyperechoic signal independent 
of the insonation angle. Furthermore, ultra-
sound can visualise potential concomitant 
inflammatory aspects of gout such as syno-
vitis and tenosynovitis. In 2015, the Outcome 
Measures in Rheumatology (OMERACT) 
Ultrasound Working Group developed defi-
nitions of structural lesions in gout.8 These 
included double contour sign (deposits of 
crystals on the surface of cartilage), tophus 
(larger hyperechoic collection of crystals), 
Key messages
 ► gout lesions can be visualised by ultrasound.
 ► The consensus- based and validated OMeracT ul-
trasound structural gout lesions show sensitivity to 
change.
 ► The double contour sign and tophus show statisti-
cally significant decreases during urate- lowering 
therapy—as early as after 3 months of treatment.
 ► Ultrasound is a promising tool for monitoring urate 
crystal deposits in patients during urate- lowering 
therapy in clinical trials and in practice.
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aggregates (small hyperechoic crystal deposits) and 
erosion (cortical damage),8 and the visualisation of 
double contour sign (DC) in joints has been included 
in the newest gout classification criteria.9 A few small 
studies have evaluated the sensitivity to change of ultra-
sound visualised urate deposits before validated defini-
tions of lesions existed10–12 and two recent studies have 
evaluated decreases in DC and tophus—as defined by 
the OMERACT group—during urate- lowering therapy 
(ULT).13 14 However, a systematic follow- up evaluating 
the sensitivity to change for all four structural lesions has 
not yet been performed in patients receiving ULT.
The primary aim of this study was to evaluate sensitivity 
to change of both ultrasound structural gout lesions and 
inflammatory changes in patients during ULT using the 
OMERACT Ultrasound Working Group 2015 definitions 
for gout lesions. The secondary aim was to assess poten-
tial correlations between changes in clinical, laboratory 
and ultrasound variables.
PaTIenTs and MeThOds
Patients
The study was a 6- month prospective, observational 
study performed at Rigshospitalet, Glostrup, Denmark. 
Eligible for inclusion were adult patients (≥18 years) with 
microscopically verified gout who initiated or increased 
ULT (allopurinol, benzbromarone or febuxostat). For 
the latter group, crystal deposits at time of intensification 
served as their baseline values. Patients were excluded if 
they had received recent (<6 weeks) glucocorticoid (GC) 
injection or oral intake of GC, or if ultrasound did not 
show signs of urate crystal deposits.
Comprehensive examinations including clinical, 
laboratory and ultrasound assessments besides patient- 
reported outcomes (PROs) were performed at baseline 
and after 3 and 6 months.
Clinical and laboratory assessments
Clinical and medical history including comorbidity, 
smoking history and alcohol consumption were obtained 
at baseline. Disease duration (time since first gout attack) 
and the joint and tendon regions ever involved in gout 
attacks were recorded.
Clinical joint examination was performed at all visits. 
Thirty joints were evaluated bilaterally in the clinical joint 
examination including all small joints at both hands and 
feet (distal and proximal interphalangeal joints at both 
hands and feet, metacarpophalangeal (MCP) and meta-
tarsophalangeal (MTP) joints) and larger joints (wrist, 
elbow, tarsometatarsal, tibiotalar and knee joints). Clin-
ical joint examination was at all visits performed by an 
independent assessor blinded to the ultrasound findings.
Routine laboratory tests including p- urate level and C 
reactive protein (CRP) were performed at all visits.
Patient-reported outcomes
PROs regarding pain (visual analogue scale (VAS)) and 
physical function (Health Assessment Questionnaire 
(HAQ)) were obtained at all visits as were numbers of 
gout attacks within the last 4 and 12 weeks.
Patient and public involvement was not included in 
this study.
ultrasound examination
All ultrasound examinations were performed using a GE 
Logiq E9 (Milwaukee, Wisconsin, USA) machine and 
ML6-15 MHz linear array transducer. Doppler settings 
were adjusted to slow flow according to published recom-
mendations.15
The ultrasound examination of patients 1–10 were 
evaluated by two ultrasonographers in collaboration 
(SNC+LT) to establish consensus about structural gout 
lesions. The rest of the ultrasound examinations (patients 
11–50) were performed by one sonographer (SNC). 
Intra- reader and inter- reader reliability were tested by 
evaluating still images on 10 patients (280 joints and 260 
tendons) among patients 11–50 (440 sites for greyscale 
(GS) synovial hypertrophy and colour Doppler (CD) 
activity, 540 sites for aggregates and tophi and 280 sites 
for erosions and DC).
All patients were examined bilaterally by ultrasound 
evaluating joints (MCP1–5, wrist, elbow, MTP1–5, tibio-
talar and knee), tendons (extensors of the wrist—scored 
as individual compartments 1–6, peroneus—longus 
and brevis scored as one—and tibialis posterior) and 
tendon insertions (triceps, quadriceps, patella—prox-
imal and distal—and Achilles). All regions were eval-
uated by standard positions16 covering all parts of the 
joints and tendons by sweeping the regions. The four 
structural OMERACT gout lesions8—DC, tophus, aggre-
gates and erosion—were scored separately using a binary 
scoring system (present/absent). In addition, synovial 
hypertrophy was graded semiquantitatively by GS and 
hyperaemia by CD according to the OMERACT scoring 
system.17 The tendons around the wrist and ankle—exten-
sors of the wrist, peroneus and tibialis posterior scanned 
bilaterally—were also evaluated for tenosynovitis (GS and 
CD) using the OMERACT tenosynovitis scoring system.18 
Synovitis and tenosynovitis were defined as a GS score ≥1 
with or without CD score ≥1.19
For each patient, sum scores of structural ultrasound 
lesions were calculated as a sum of each individual lesion 
across all scanned sites. A crystal sum score was calculated 
for each patient by adding tophus, DC and aggregate sum 
scores. Furthermore, GS synovial hypertrophy sum scores 
and CD activity sum scores were calculated by adding 
scores from all joints and tendon sheaths (range, 0–132).
The duration of the ultrasound examination was 
approximately 60 min per visit.
statistical analysis
Descriptive statistics were used to summarise the baseline 
data. Patients’ baseline characteristics were presented as 
means with SD for normally distributed variables and as 
medians with ranges and IQRs for non- normally distrib-
uted variables.
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Table 1 Demographic and baseline characteristics (n=50)
Variable Value
Age, years, mean (SD) (range) 63.9 (14.5) (30–88)
Male sex, n (%) 48 (96%)
Disease duration, months, median (IQR) 
(range)
78 (24; 132) (1–468)
No of gout attacks within 12 weeks, 
median (IQR) (range)
2 (1; 4) (0–6)
No of gout attacks within 4 weeks, median 
(IQR) (range)
1 (1; 1) (0–4)
VAS pain, median (IQR) (range) 35 (15; 55) (0–95)
HAQ, median (IQR) (range) 0 (0; 0.375) (0–1.375)
No of tender joints (0–60), median (IQR) 
(range)
2 (1; 4) (0–18)
No of swollen joints (0–60), median (IQR) 
(range)
1 (0; 2) (0–14)
P- urate (mmol/L), mean (SD) (range) 0.49 (0.10) (0.32–0.78)
No of patients on urate- lowering therapy at 
inclusion (%)
9/50 (18%)
Self- reported gout attacks (ever) (%)
  Forefoot 43 (86%)
  Midfoot 9 (18%)
  Ankle 27 (54%)
  Knee 12 (24%)
  Finger and/or wrist 16 (32%)
  Elbow 1 (2%)
Body mass index, kg/m2, mean (SD) 
(range)
28.7 (5.5) (18.9–41.9)
Units of alcohol per day, median (IQR) 
(range)
0.5 (0; 2) (0–8)
No of smokers (%) 25 (50%)
HbA1c (mmol/mol), mean (SD) (range) 41.3 (8.5) (29–68)
Cholesterol (mmol/L), mean (SD) (range) 4.9 (1.3) (2.7–8.4)
CRP (mg/L), median (IQR) (range) 7.0 (0.9; 24) (0.3–120)
eGFR (mL/min), median (IQR) (range) 72.5 (57; 90) (21–90)
No of patients with comorbidities (%) 39 (78%)
Most common comorbidities (n (%))
  Cardiovascular diseases 17 (34%)
  Diabetes 13 (26%)
  Hypertension 15 (30%)
  Kidney disease 18 (36%)
CRP, C reactive protein; eGFR, estimated glomerular filtration rate ; 
HAQ, Health Assessment Questionnaire; VAS, visual analogue scale.
The inter- observer and intra- observer reliability of 
scoring images were assessed according to kappa (κ) 
statistics on static images. Intra- observer coefficients were 
evaluated on pairs of measures performed by the same 
sonographer at each site on static images. Kappa values 
of 0–0.20 were considered poor; 0.20–0.40, fair; 0.40–
0.60, moderate; 0.60–0.80, good; and 0.80–1, excellent, 
as proposed by Landis and Koch.20
Changes in both clinical, laboratory and ultrasound 
findings were presented as means and medians with 
ranges and IQRs. Changes over time in quantitative 
results within groups were analysed using Wilcoxon 
signed- rank test.
Correlation analyses were performed using Spear-
man’s rank- order correlation assessing individual rela-
tions between changes in biochemical (most importantly 
p- urate), clinical and ultrasound findings.
No data imputation was used. P values <0.05 were 
considered statistically significant. All statistical analyses 
were performed based on a statistical analysis plan and 
analysed using SAS Enterprise Guide V.7.15.
ResulTs
A total of 50 patients were included in the study, and of 
these 46 (92%) completed 3 months’ follow- up and 41 
(82%) 6 months’ follow- up. Baseline characteristics of 
the cohort are shown in table 1.
Baseline characteristics, except for body mass index 
(BMI), did not differ statistically significantly between 
patients completing versus not completing the 6 months’ 
follow- up (all p values >0.05, data not shown). The BMI 
was higher in the drop- out group compared with the 
completing group (mean BMI 32.5 vs 27.8, p=0.02).
Reliability
Inter- reader and intra- reader reliabilities were excellent 
for both DC (κ 0.81 and 0.95, respectively) and tophus (κ 
0.81 and 0.91, respectively). The inter- reader reliability 
was good for aggregates (κ 0.71), erosion (κ 0.68) and 
CD activity (κ 0.72), whereas the intra- reader reliability 
for these findings were excellent (κ 0.84, 0.83 and 0.92, 
respectively). For GS synovial hypertrophy, both inter- 
reader and intra- reader reliability was good (κ 0.75 and 
0.79, respectively).
sensitivity to change
The data for clinical and laboratory assessment, the PROs 
and the ultrasound findings at baseline, 3 months’ and 6 
months’ follow- up are summarised in table 2.
laboratory and clinical parameters
P- urate and CRP both showed a statistically significant 
decrease at 6 months’ follow- up (table 2). Mean p- urate 
decreased from 0.49 mmol/L at baseline to 0.36 mmol/L 
at 3 months’ follow- up and 0.33 mmol/L at 6 months’ 
follow- up (p<0.001). A p- urate level <0.36 mmol/L was 
obtained by 24/46 (52%) at 3 months’ follow- up and 
32/41 (78%) at 6 months’ follow- up.
The clinical parameters including numbers of affected 
joints, numbers of gout attacks and patients’ VAS pain 
decreased statistically significantly from baseline to 
follow- up at 3 and 6 months and, furthermore, VAS 
pain—as the only parameter of these—showed a contin-
uous decrease from 3 to 6 months’ follow- up (table 2). 
HAQ showed only a numerical decrease during follow- up. 
Figure 1A summarises the course of clinical parameters 
and PROs during follow- up.
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Figure 1 Course of clinical parameters including patient- reported outcomes (A) and ultrasound findings (B) during the 
6 months’ follow- up period. Box plot explanation: 75th percentile, upper edge of box; 25th percentile, lower edge of box; 
median, line inside box; mean, circle inside box. *Wilcoxon signed- rank test showing p values <0.05. DC, double contour sign; 
HAQ, Health Assessment Questionnaire; VAS, visual analogue scale pain.
Figure 2 Sequential ultrasound investigations in patients during urate- lowering therapy. Left column (A–C): ultrasound 
of the first metatarsophalangeal joint. Longitudinal dorsal view. Ultrasound shows regression of double contour sign 
(arrowheads) when observed from baseline (A) to 3 (B) and 6 (C) months’ follow- up. Mid column (E–F): ultrasound of the first 
metatarsophalangeal joint. Longitudinal medial view. Ultrasound shows reduced tophus size (arrows) from baseline (D) to 
3 months’ (E) and 6 months’ (F) follow- up. A double contour sign is observed at baseline (D, arrowheads), but is no longer 
visible at 3 and 6 months’ follow- up (E–F). Right column (G–I): ultrasound of the first metatarsophalangeal joint. Longitudinal 
dorsal view. Ultrasound shows reduction in urate deposits from baseline (G), where deposits are seen as a small tophus (large 
arrows), to 3 months’ follow- up (H), where deposits are reduced to aggregates (small arrows). In addition, a double contour 
sign is observed at both baseline and 3 months’ follow- up (arrowheads). At 6 months’ follow- up (I), no urate deposits can be 
observed in the joint.
Ultrasound parameters
The course of both structural (DC, tophus, aggregates and 
erosion) and inflammatory (GS synovial hypertrophy and 
CD activity in joints and tendon sheaths) ultrasound find-
ings during follow- up are shown in table 2 and figure 1B.
Structural lesions
The DC and tophi sum scores decreased statistically signif-
icantly from 0 to 3 and from 3 to 6 months’ follow- up, 
whereas the decreased in aggregate sum score only 
occurred late in the follow- up (3–6 months). The summa-
rised crystal score—DC, tophi and aggregates added—
decreased statistically significant from both 0–3 and 3–6 
months’ follow- up. The erosion sum score did not change 
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Figure 3 Distribution and course of ultrasound lesions in patients with gout during the 6 months’ follow- up period. Bilateral 
assessment of joint and tendon sites. Within- group changes over time were analysed using Wilcoxon signed- rank test. 
*p<0.05. CD, colour Doppler activity; Comp. I–VI, compartments I–VI; DC, double contour sign; GS, greyscale synovial 
hypertrophy; MCP, metacarpophalangeal joint; MTP, metatarsophalangeal joint; Patella Dis, distal patella insertion; Patella Pro, 
proximal patella insertion; Tib Post, tibialis posterior tendon.
significantly during follow- up. Figure 2 shows examples of 
the changes in DC and tophi in patients during follow- up.
Inflammatory lesions
GS synovial hypertrophy and CD activity (in joint and 
tendon sheaths) both decreased statistically significantly 
at 6 months’ follow- up; CD activity already at 3 months’ 
follow- up.
distribution of lesions
The distribution of structural and inflammatory ultra-
sound lesions in joints and tendons are shown in 
figure 3A,B.
The MTP1 joints were the most common location for 
all four structural lesions and for both inflammatory 
lesions. Patients had on average 1.1 DCs and 1.4 tophi 
bilaterally in MTP1 joints. The second most affected 
joints were the MTP2 joints, where aggregates and DC 
were common while tophus formation less frequent, 
and for inflammatory lesions primarily GS synovial 
hypertrophy was observed. For MTP3–5 and MCP joints, 
involvement was less common, and if affected, urate 
deposits were mostly seen as aggregates. Tophus forma-
tions in these joints were almost solely found in MCP1 
and MTP5 joints. The knee joints were common sites for 
DC.
As to the tendons, the most common sites for urate 
deposits were the peroneus tendons and the Achilles, 
quadriceps and patella (both proximal and distal) tendon 
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insertions. Tenosynovitis was most commonly found in 
the peroneus tendons.
Changes in structural lesions at different locations during 
follow-up
Figure 3C shows the course of the structural lesions in 
joints and tendons. At joint level, statistically significant 
decreases in urate deposits were found at MTP1s for 
tophus formation, MTP1–3s and knees for DC forma-
tion, and MTP4s for aggregates. In tendons, a trend 
for a decrease in tophus formation during follow- up 
was observed—less pronounced for aggregates—but no 
statistically significant changes were observed.
Correlation between clinical, laboratory and ultrasonographic 
findings
The individual correlations between the course of 
different variables were investigated (see online supple-
mentary table 1). In general, no strong correlations were 
found between the individual changes in any clinical, 
laboratory and ultrasound findings (r<0.50)—except 
between parameters which were directly related (eg, 
crystal sum score and its components). Weak, positive 
correlations were found between changes in p- urate and 
changes in both DC and the combined ultrasound ‘crystal 
sum score’ (r=0.430 and r=0.369, respectively, p≤0.02) 
as the only two parameters. Correlations between other 
investigated parameters were non- existing or weak (see 
online supplementary table 1).
dIsCussIOn
This study evaluates the sensitivity to change of all four 
consensus- based and validated OMERACT ultrasound 
structural gout lesions. DC and tophus showed statisti-
cally significant decreases during ULT—as early as after 3 
months of treatment. This indicates that these ultrasound 
measures of urate deposition are sensitive to change as 
a response to even a short- term use of ULT using the 
applied binary scoring system; thus, ultrasound for moni-
toring urate deposits during therapy is a promising tool 
in both clinical trials and in practice. Furthermore, ultra-
sound signs of inflammation decreased significantly at 
6 months’ follow- up, supporting the ability of ultrasound 
for objective and sensitive monitoring of synovitis and 
tenosynovitis in gout.
The disappearance of tophi and DC as a response to 
ULT as seen in our study is in line with previous studies. 
Small cohort studies10–13 and one recent larger cohort 
study14 showed disappearance of DC10 11 13 14 and decrease 
in tophus size visualised by ultrasound12–14 in response 
to ULT. Also in line with our study, an improvement in 
clinical parameters and synovial Doppler signal was seen 
in parallel with dissolution of urate deposits.13 21 Previous 
studies have noted that it seems easier to clear the carti-
lage deposits than the tophi,11 13 although tophi have 
shown responsiveness when assessed by size after only 3 
months of treatment.14 This appears also to be the case 
in our study since a more pronounced decrease in mean 
DC sum scores was observed compared with mean tophus 
sum scores. The fact that tophus sum score in this study 
decreased statistically significantly after only 3 months of 
therapy even when scored binarily was probably due to 
the large number of scanned sites—making significant 
results more likely to occur. As exemplified by figure 2, 
small tophi dissolved within the first 3 months, whereas 
larger tophi showed a tendency to only decrease in size as 
a response to the 6 months of ULT.
In our study, aggregates showed a statistically signif-
icant decrease during follow- up, but the decrease 
occurred later and appeared less pronounced compared 
with DC. The course of aggregates in patients receiving 
ULT can be unpredictable since tophi potentially could 
dissolve into aggregates in the process of disappearing (as 
exemplified in figure 2). Thus, even though aggregates 
resolve during therapy, others may be formed. Previous 
studies with focus on diagnostic features of ultrasound 
in gout4–7 have only established high specificities for DC 
and tophus, and the role of aggregates in the evaluation 
of gout patients is yet to be clarified.
The large number of scanned joints and tendons in 
our study allowed us to establish both the locations most 
commonly affected by gout and if all lesions seemed 
to respond equally well to ULT. Structural ultrasound 
lesions were by far most commonly found in MTP1 joints, 
where patients on average had >1 of all four structural 
lesions. MTP2–4s, knee joints and several lower extremity 
tendon regions were also commonly affected. The loca-
tions most commonly affected by urate depositions were 
also the locations most responsive to treatment. Upper 
extremities urate depositions in joints and tendons were 
observed, but to a much lower extent compared with 
lower extremity involvement, which is in accordance with 
previous studies.22–24
A significant correlation between changes in the struc-
tural lesions DC and crystal sum scores and changes in 
p- urate was found in our study, whereas p- urate changes 
did not correlate to either changes in tophi or aggre-
gates sum scores. This concurs with previous studies5 13 25 
also finding DC but not tophi to be correlated to p- urate 
levels. The lacking correlation between changes in tophi 
sum scores and p- urate may be explained by tophi repre-
senting larger collections of urate deposits and therefore 
dissolving slowly compared with DC. A more responsive 
assessment of crystal changes such as a semiquantitative 
score or a continuous measure of tophus size may poten-
tially show a positive correlation with p- urate levels as 
observed in previous studies.12 14
Our data revealed significant improvements in both 
ultrasound, clinical and biochemical signs of inflam-
mation during follow- up. GS synovial hypertrophy and 
CD activity in both joints and tendon sheaths decreased 
during treatment indicating a rapid fall in inflamma-
tory activity, which is supported by a decrease in swollen 
and tender joint counts, improvement in PROs and a 
decrease in CRP. The fact that inflammatory markers 
and patient’s self- perceived symptoms decreased as ULT 
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was intensified were probably related to adjuvant treat-
ment with colchicine, which were given to all patients in 
this study in accordance with international guidelines.26 
Otherwise, an increased rate in flares would have been 
expected since this is in general described when ULT is 
initiated alone.27
The strengths of our study is the large patient cohort 
compared with most previous performed studies (second 
largest patient population). Furthermore, lesions are 
scored based on well- established consensus- based defini-
tions, optimising the reliability of the results and facili-
tating comparison to future studies. Finally, the scanned 
regions included numerous joints and tendons enabling 
us to evaluate the distribution of lesions.
Limitations of the study include the lack of a control 
group and that the operator was unblinded to the treat-
ment of the patients. However, the operator was neither 
the person performing the clinical joint examination 
nor the person responsible for adjusting ULT. Another 
limitation was that ultrasound assessment was performed 
by only one operator. However, the inter- reader reliability 
between operators were found to be excellent for DC and 
tophus and good for the remaining lesions. These inter- 
reader reliabilities are—especially for DC and aggre-
gates—considerably higher than shown in the initial 
validation study28; thus, our study indicates that intensive 
training and calibration between operators could improve 
the reliability of the scoring of lesions. Finally, the scoring 
of lesions was performed using a binary scoring system, 
and this limits the sensitivity to minor changes in lesions 
during follow- up. We chose to score lesions binarily since 
no consensus exists on a standardised way to score lesions 
either semiquantitatively or by measurements in a proven 
reproducible way.
The ultrasound examinations in our study were time 
consuming since multiple joints and tendons were 
scanned, and this would not be feasible in routine clin-
ical practice. However, this extended examination was 
performed to help identifying predilection sites for struc-
tural gout lesions, and the study demonstrated that the 
areas most commonly affected were also the areas most 
responsive to treatment; thus, a reduced joint scan could 
potentially be used. This study was not designed to select 
proper areas for reduced joint/tendon set inclusion since 
this is preferably done in diagnostic settings in order to 
determine the minimum amount of sites to distinguish 
patients with gout from patients with no gout. However, 
the common involvement and rapid responsiveness to 
treatment of lesions in MTP1–3 and knee joints indicate 
that evaluation of these areas is presumably essential.
A potential benefit of using routine ultrasound exam-
ination in patients with gout in daily clinical practice 
could be as a motivational instrument for both the 
physician and the patient. The ability of ultrasound to 
visualise the disappearing of urate deposits over time 
could improve the motivation for both the physicians—
to prescribe adequate treatment adjustments—and the 
patients—to increase treatment adherence. Both these 
aspects are compromised in many patients with gout.29–31
In conclusion, our observational study demon-
strates that performing ultrasound for specific struc-
tural features of gout such as tophi and DC, defined as 
proposed by the OMERACT ultrasound working group, 
at the initiation of ULT and during follow- up seems to 
be a sensitive way to detect and monitor the dissolution 
of urate deposits. Future studies should address what 
sites should be included in a reduced joint/tendon set 
for evaluating gout lesions and whether more sensitive 
monitoring could be obtained by using a semiquantita-
tive scoring system.
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